Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alissa Welsh

Allergy Webster, TX Medical Doctor

NPI 1831509116 CMS profile 472737

561 W Medical Center Blvd Ste G, Webster, TX 77598

Open in the dashboard

General payments

$8,882

441 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alissa Welsh of Webster, TX is reported in the CMS Open Payments database as having received $8,882 across 441 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,205 93
2024 General $1,123 55
2023 General $1,488 84
2022 General $1,027 55
2021 General $1,185 67
2020 General $966 56
2019 General $887 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alissa Welsh
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Alissa Welsh were reported at $2,205. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Alissa Welsh Allergy median Middle half National median
2019 $887 $506 $151–$1,337 $163
2020 $966 $409 $108–$1,162 $114
2021 $1,185 $549 $125–$1,485 $132
2022 $1,027 $666 $161–$1,594 $149
2023 $1,488 $780 $186–$1,916 $160
2024 $1,123 $1,031 $271–$2,196 $164
2025 $2,205 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,809 78 payments
  2. Genzyme Corporation $924 41 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $889 43 payments
  4. GlaxoSmithKline, LLC. $871 75 payments
  5. CSL Behring $769 39 payments
  6. Novartis Pharmaceuticals Corporation $617 32 payments
  7. Grifols USA, LLC $557 31 payments
  8. Regeneron Healthcare Solutions, Inc. $329 10 payments
  9. ARS Pharmaceuticals Operations, Inc. $282 10 payments
  10. Pfizer Inc. $217 11 payments
  11. Other $1,616 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,866 440 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT $1,413 64 payments
  2. TEZSPIRE $743 19 payments
  3. CUVITRU $644 33 payments
  4. FASENRA Respiratory $638 26 payments
  5. TRELEGY ELLIPTA $559 50 payments
  6. Hizentra $433 20 payments
  7. Xembify $428 24 payments
  8. FASENRA Respiratory $422 20 payments
  9. XOLAIR $372 20 payments
  10. AIRSUPRA $302 5 payments
  11. Other $4,481 220 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$128,547

Of which drugs: $56,509

Medicare patients

295

Average age 74

Services billed

6,303

197 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 31%
Diabetes 26%
COPD 20%
Osteoporosis 20%
Chronic kidney disease 17%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$166 23 —
XOLAIR
$146 — —
CUVITRU
$82 — —
TEZSPIRE
$80 — —
NUCALA
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record